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Abstract: Airway cancers have been increasing in recent years. Tracheal resection is commonly
performed during surgery and is burdened from post-operative complications severely affecting
quality of life. Tracheal resection is usually carried out in primary tracheal tumors or other neoplasms
of the neck region. Regenerative medicine for tracheal replacement using bio-prosthesis is under
current research. In recent years, attempts were made to replace and transplant human cadaver
trachea. An effective vascular supply is fundamental for a successful tracheal transplantation. The use
of biological scaffolds derived from decellularized tissues has the advantage of a three-dimensional
structure based on the native extracellular matrix promoting the perfusion, vascularization, and
differentiation of the seeded cell typologies. By appropriately modulating some experimental
parameters, it is possible to change the characteristics of the surface. The obtained membranes could
theoretically be affixed to a decellularized tissue, but, in practice, it needs to ensure adhesion to the
biological substrate and/or glue adhesion with biocompatible glues. It is also known that many of the
biocompatible glues can be toxic or poorly tolerated and induce inflammatory phenomena or rejection.
In tissue and organ transplants, decellularized tissues must not produce adverse immunological
reactions and lead to rejection phenomena; at the same time, the transplant tissue must retain the
mechanical properties of the original tissue. This review describes the attempts so far developed and
the current lines of research in the field of tracheal replacement.
Keywords: bioengineering; biocompatible materials; scaffolds; surgical biotechnologies
1. Introduction
Airway diseases requiring surgical treatment have been increasing in recent years,
due to the higher incidence of respiratory tract cancer (19% of tumors in Italy) [1]. Tracheal
resections frequently cause disability, due to the loss of phonation and the presence of
a permanent tracheostomy (that represents an easy access to pathogens responsible of
recurrent lower respiratory tract infections, often lethal). Laryngotracheal stenosis is the
main cause of re-intervention in the upper respiratory tract.
Tracheal resections inferior to 50% of the tracheal length are currently repaired by
end-to-end anastomosis [2]. Any excessive tensions are approached by different techniques,
including neck flexion, transcervical mobilization of the trachea and mainstem bronchi and
the suprahyoid laryngeal release, transthoracic elevation of the right hilus with division of
the pulmonary ligament, intrapericardial dissection of the pulmonary trunk, and incision of
the tracheal intercartilaginous ligaments. The extent of tracheal resection length of depends
on age, posture, and severity of disease [3–5].
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Extensive lesions of the trachea, including tumors or stenoses overcoming half of the
organ in adults (6 cm) or one third in children, may require prostheses [6].
The apparent simplicity of the “windpipe” encouraged studies with tubular substitutes
including biosynthetic materials, auto- and allografts. The characteristics of an ideal
tracheal substitute include lateral rigidity and longitudinal flexibility, and the presence of a
ciliated respiratory epithelium covering the inner surface. The implant must be airtight and
not produce chronic inflammation, excessive granulation tissue, infections, or erosions [7].
Materials should be biocompatible, nontoxic, non-immunogenic, and non-carcinogenic
permitting epithelial covering. At the same time, materials should not migrate or producing
erosion. Stenoses, increased secretions, and bacterial colonization are frequently observed
phenomena [8]. This review describes the current approaches and progresses in the field of
biosynthetic substitutes for tracheal replacement.
A systematic search of the literature electronic databases Web of Science, Scopus,
and PubMed was performed. The search ranged from January 1947 to December 2020 by
using the following keywords: tracheal reconstruction, artificial trachea, tracheal scaffolds,
tracheal reconstruction, tracheal tissue regeneration. More than 3800 studies were identified.
The selection was focused on whole tracheal reconstruction and included preclinical and
clinical investigations. Twelve hundred papers were selected according to journal citations
and indexing.
An electronic search on Clinicaltrial.gov was also performed with the same keywords,
but only five results were available.
In Table 1, a summary of the main tracheal reconstruction techniques is reported.
Table 1. Tracheal reconstruction techniques.
Techniques Methods Features Results
Standard tracheal
reconstruction
Tracheal dilatation with rigid
bronchoscope [3,6] High recurrence rates (90%)
Laser surgery with placement
of an endoluminal stent [9] 30–40% recurrence rate
Surgical resection [7,10]
Post-operative period burdened
by several complications (up to





Early stenosis, necrosis, undergo
liquefaction, and graft rejection in




Allografts need to be
revascularized, cryopreserved




matched aortic allografts [12]
Supported by a stent to prevent
airway collapse and covered
circumferentially with a local
muscle flap to promote
neovascularization
Aortic matrices played a





cytokines, and growth factors
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Table 1. Cont.





Removal of cell from the ECM
and preserving the mechanical
and bioinductive profile of the
graft
Breaking of cell membrane














with an artificial pleura patch
POSS-PCU cellularized with stem
cells by dynamic culture in a
bioreactor
PCL: progressive
improvement of the tracheal
respiratory space
POSS-PCU: partial epithelial







seeded on a non-adherent surface
develop neotissue by adhering to
each other)
Fabricated sheets of cartilage
obtained from the auricular
cartilage of New Zealand
white rabbits in combination
with a muscle/silicone
construct
Self-assembly in TETG has
been reported using human
MSC-derived cartilaginous
rings and cylinders generated
through a custom ring-to-tube
assembly system
2. Main Body
2.1. Anatomical Properties of the Trachea
The trachea is a flexible fibro-elastic tube that connect the larynx and the lungs [20].
The anterior and lateral sides consists of a pile of C-shaped rings of hyaline cartilage.
Posterior wall is only covered with smooth muscle. The inner surface is internal with a
pseudostratified columnar epithelium containing goblet cells. Tissue-engineering tech-
niques for building a trachea require careful considerations of the anatomical layers: over
epithelium and cartilage, there is a connective tissue that acts as a matrix for blood vessels
and nerves, but it also has a supportive function for exocrine glands, an important source
of mucus and fluids.
2.2. Standard Tracheal Reconstruction
Current trends for tracheal reconstruction include tracheal dilatation with rigid bron-
choscope, laser surgery with placement of an endoluminal stent, and surgical resection.
Unfortunately, the first two methods are burdened by very high recurrence of stenosis (90%
for endoscopic dilation and 30–40% for laser treatment) [9]. Tracheal resection, therefore,
represents the gold standard for the treatment of tracheal stenoses, especially in those cases
in which the stenotic tract is lower than 4 cm in length [21]. Tracheal resection is usually
carried out in primary tracheal tumors or other neoplasms such as thyroid carcinoma
infiltrating the trachea [10], thymoma [22], or even in endotracheal post-intubation steno-
sis [23], in vocal cords palsy [24], tracheal atresia [25], or tracheo-esophageal fistula [26].
The post-operative period could be burdened by several complications (up to 20% of cases)
that include recurrent stenosis, permanent tracheostomy, and even death [27].
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2.3. Approaches to Tracheal Reconstruction
2.3.1. Allografts
Tracheal Allografts
Fresh tracheal allografts have demonstrated early stenosis, necrosis, undergo lique-
faction [2,11,28–30], and more important, develop graft rejection in the absence of im-
munosuppressive therapy. Tracheal allografts carry antigens [31] represented by HLA-DR
expressed on epithelial cell surface. These antigens activate T lymphocytes and thereby
trigger graft rejection. Chemical or physical treatments have also been proposed in clinical
applications [4]. A high irradiation of allografts permits to avoid immunosuppression
in the host, but the implant needs indirect vascular supply [32]. Chemical treatments do
not induce rejection, but nope cartilage and epithelium formation [33]. Formalin-fixed
allografts from cadavers showed reduced allogenicity and complete epithelization but
require frequent bronchoscopies to remove exuberant granulation tissue and ultimately
become malacic [34,35]. Treatments based on very low temperature freezing are effective
to induce loss of class II HLA [36–38], and a long period of cryopreservation may help
to maintain a better patency of tracheal allografts [39,40]. Cartilaginous alterations often
occur [41–43], probably due to a deficient blood supply [44–46].
Aortic Grafts
Seven preclinical studies on a sheep model showed explored allogeneic aortic grafts
as airway substitutes [47]. The aortic scaffold served as a matrix for de novo generation of
cartilage. Bone marrow mesenchymal stem cells may play a role in modulating the process
of regeneration [48]. This assumption led to the first human application in patients with
extensive tracheal diseases [49–51].
De novo generation of cartilage in cryopreserved aortic allografts has been reported [12]
in a small series of tracheal lesions using a cryopreserved non-AB0 matched aortic allograft
supported by a stent to prevent collapse. Allografts were covered with a muscle flap to
promote neovascularization and prevent fistulisation. Stents were removed 5 to 39 months
after transplantation. The 90-day mortality rate was low. The regeneration of a mixed
respiratory epithelium was observed on superficial allograft biopsies. De novo generation
of cartilage cell of recipient within the aortic allografts was observed [52–55].
2.3.2. Regenerative Medicine and Tissue Engineering
Regenerative medicine is an emerging interdisciplinary field of research and clinical
applications focused on the repair, replacement, and regeneration of cells, tissues, or
organs to restore damaged function from any cause, including congenital defects, diseases,
and trauma [56]. This field includes therapeutic areas that were initially thought to be
separate, such as cell therapy and tissue engineering (in vitro creation of tissues/organs for
a subsequent transplantation as fully functional organs or tissue grafts) [57,58]. In particular,
in cell therapy, the use of a biocompatible/bioabsorbable scaffold is not required, whereas in
tissue engineering, a tridimensional biocompatible/bioabsorbable structure is necessary to
support the regeneration of the damaged tissue [59]. These two sectors include substitution
(transplantation), repair (exogenous cell therapy), or tissue regeneration (mobilization of
endogenous cell pools, such as stem cells) [60,61].
In 2008, a tissue engineered tracheal graft (TETG) was implanted in a patient with
severe bronchial stenosis following treatment for tuberculosis [62]. Since then, nine reports
of TETG implantation in humans have been published, with a total of 15 reported patients
who have undergone tracheal replacement [54,62–68]. The brilliant results reported by
Macchiarini et al. have been made opaque from the revelation that most patients died after
the implantations [52,63,68–70].
Tissue engineering, as a branch of regenerative medicine, has emerged as a more recent
approach for restoring damaged tissues. Research in the field of tissue engineering has the
objective of creating new materials that do not give rise to unwanted reactions on the part
of the host organism and that are able to promote the regeneration of the damaged tissue
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or organ. Different strategies can be adopted [54]: insemination of cells on an implanted
scaffold, implantation of tissue grown in vitro on a scaffold, or scaffold implantation
without cells to support tissue regeneration in situ. Cell adhesion, proliferation, and
differentiation are strongly influenced by the microenvironment as well as by the size,
geometry, pore density, and the properties of the scaffold surface [61,71]. For all these
approaches, the scaffold must provide a three-dimensional structure that will support the
growth of a new tissue with biological properties comparable to that of the tissue that
needs to be replaced [72].
The success in creating functional engineered tissues lies in the integration of cells,
biomaterials, and signaling systems, also known as the tissue engineering triad [73].
The homing of stem cells into the injured area may be driven through two mechanisms:
incorporation into an engineered tissue or attraction to the wound site. In the field of
tracheal replacement, in an attempt to reproduce the static and dynamic features of the
organ, many different scaffolds have been explored, but they can generally be classified as
decellularized tracheal constructs, biosynthetic, or scaffold-free constructs.
Decellularized Tracheal Scaffold
The development of decellularized tracheal scaffold came in response to initial out-
comes obtained using cadaveric human allografts. Decellularization provides a not im-
munogenic extracellular matrix (ECM) [74–76].
Because the mechanical properties of the tracheal ECM come from composition of
collagen, glycosaminoglycans, and elastin, decellularized tracheas maintain biomechanical
properties of native trachea. ECM plays an important role in tissue formation through
chemoattraction, cell support, and signaling [75]. This phenomenon has been largely
demonstrated by several observations of chondrocyte repopulation, re-epithelialization,
muscle bundle formation, and the growth of serous glands and nerve fibers [77,78]. De-
cellularization protocols range from 3 days to 12 weeks to disrupt cell membranes and
denature proteins [62,79–82]. Physicochemical characteristics of the decellularized scaffold
promote perfusion, vascularization, and differentiation of the seeded cells. Briefly, decellu-
larization begins with the rupture of the cell membrane by means of physical treatments or
ionic solutions, followed by the separation of cellular components from the extracellular
matrix through enzymatic treatments, the solubilization of the cytoplasmic components
using detergents, and ends with the removal of cellular debris; these stages can be coupled
with the mechanical stirring so as to increase their effectiveness. Once decellularization
is complete, chemicals are removed. An effective vascular supply is fundamental for a
successful tracheal transplantation: Delaere et al. [2] focused their attention on this aspect
with poor results; Tan et al. [83] replaced a tract of about 5 cm of the left bronchus, removed
for tumor, with a stent of Nitinol coated with porcine dermis [84]. In the study, the stent was
continuously irrigated with a solution of Ringer’s lactate with added neoangiogenic factors
and antibiotics. The patient survived and was discharged on month after implantation.
Synthetic Polymers Scaffolds and Three-Dimensional Printers
Several research groups have focused their efforts on synthetic polymers scaffolds
for airway replacement. Three-dimensional printing permits to fabricate scaffold varying
composition, size, and porosity of construct [85]. Copolymers of polylactic and polyglycolic
acid [PLGA] as well as copolymers composed of polyphatic acid and polycaprolactone
[PCL] have been tested in vitro as tubular scaffolds, to obtain a tracheal substitute. In this
case, the construct was initially cellularized with mesenchymal stem cells that guaranteed
complete resorption of the prosthetic material and deposited ECM [86–88]. Unfortunately,
the process did not lead to a complete ECM formation, which is essential for the mechanical
and metabolic support of the newborn tracheal tissue.
Electrospinning of soluble polymers is a promising technique for building three-
dimensional porous structures [71]. Hinderer et al. [14] made a composite PCL–gelatin–
decorine scaffold with a three-dimensional structure and pores of an average size of
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14.4 ± 6.4 µm; the tubular scaffold was then inserted in a dynamic circuit. The results
demonstrated a uniform composition of the scaffold, but a poor mechanical resistance and
the presence of cells only at the outer surface of the construct. Gustafsson et al. [89] investi-
gated the effects of culturing rat mesenchymal stromal cells on a polymeric scaffold coated
with adhesion proteins. In this study, a cellular colonization was registered throughout the
whole surface of the structure, regardless of the presence of adhesion molecules. Following
this idea, Shi et al. [90] realized a copolymer of N-carboxyethylchitosan/nanohydroxyapatite,
potentially suitable for airway replacement. However, in this first phase, the results re-
ported from in vitro tests seem to be preliminary for in vivo application.
In Vivo Tracheal Scaffold Implants
Tracheal scaffolds have been also tested in vivo to evaluate tissue regeneration and
healing after segmental tracheal resection. In 1994, Vacanti et al. [91] produced a tubular
scaffold from sheets of fibrous polyglycolic acid cellularized with chondrocytes. The
scaffolds were implanted in four rats, as substitutes for 4–6 tracheal rings. Unfortunately,
the animals died soon after surgery. Kanzaki et al. [92] proposed a model of prevascularized
Dacron support covered by a layer of rabbit tracheal epithelial cells. These constructs had a
better outcome in a rabbit model showing mature, pseudostratified columnar epithelium
that partially covered the scaffold four weeks after transplantation.
PCL was also employed to build a possible tracheal substitute. The prosthesis was
tested in vivo in rabbits. The main advantages of the polymer include a slow degra-
dation time and good mechanical characteristics [93]; unfortunately, the formation of a
high amount of granulation tissue caused a stenosis in the center of the construct and,
subsequently, the death of the animals.
A copolymer of lactic acid and PCL was used to produce a sponge-like tubular
structure reinforced, with a PGA structure coated with gelatin, to prevent air leak, was
proposed by Tsukada et al. [15]. The graft of about 6 cm in length was implanted on a
sheep, performing a terminal end-to-end anastomosis and placing a silicone stent inside
to avoid collapse. Nine months after implantation, the scaffold did not undergo, and the
animal died consequently.
A different approach for the development of an artificial trachea was followed by
Naito et al. [94]. In their experiments, fibroblast and collagen hydrogels, mechanically
supported by osteogenically induced mesenchymal stem cells (MSC) in ring-shaped 3D-
hydrogel cultures, were applied in a model of rat trachea injury. Tube-shaped tissue was
constructed from mixtures of rat fibroblasts and collagen in custom-made casting molds.
Ring-shaped tissue was constructed from mixtures of rat MSCs and collagen and fused
to the tissue-engineered tubes to function as reinforcement. Unfortunately, in this case,
six of the nine animals died during implantation, while three of them survived for 24 h
and died the day after. Most of the tissue-engineering tracheal approaches have been
focused on the development of scaffolds for circumferential defects repair. Less common
scaffolds are Y-shaped substitutes for bifurcation repair. A Y-shaped scaffold made of
Marlex mesh reinforced with polypropylene and coated with collagen was implanted
in 20 dogs: 14 out of them died after experimentation due to obstruction, loss of air, or
necrosis [95]. Huang et al. [16], on the other hand, used a PCL-based scaffold on a 47-year-
old woman affected by tracheomalacia after tubercular disease. During surgery, to ensure
better sealing and integration of the scaffold, it was coated with an artificial pleura patch.
During the post-operative three months, the patient underwent serial bronchoscopies
that allowed them to demonstrate a progressive improvement of the tracheal respiratory
space (passing from 0.3 cm in maximum diameter to 1 cm). Jungebluth et al. [68] in 2011
published the results of a tracheo-bronchial transplant carried out urgently on a 37-year-
old man suffering from recurrence of mucoepidermoid carcinoma involving the distal
trachea. The patient had previously undergone tracheal resection and radiotherapy, but
due to tumor recurrence, as a life-saving intervention, a polymer in POSS-PCU [polyhedral
oligomericsilsesqui-oxane (POSS) covalently linked to poly (-carbonate-urea) urethane
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(PCU)], cellularized with stem cells by dynamic culture in a bioreactor, was implanted to
substitute the affected tract (6 cm of distal trachea and 2 cm of the proximal main bronchi).
The results obtained were good and showed a partial epithelial colonization of the polymer,
as witnessed by biopsies carried out during bronchoscopic controls. After five months, the
patient showed no neoplastic recurrence and a clear improvement in pulmonary function
indices [96]. There are no data concerning long-term results, and there is an ongoing ethical
debate on the procedure carried out [97].
Scaffold-Free Constructs
Scaffold-free constructs do not require cell seeding or an external three-dimensional
structure by means of self-organization and self-assembly techniques.
Self-organization techniques involve the formation of new tissue with the application
of external forces [17]. These techniques include bioprinting and cell-sheet engineering.
As an example, fabricated sheets of cartilage obtained from the auricular cartilage of
New Zealand white rabbits have been used in combination to a muscle/silicone construct
to create a neotrachea that was ectopically cultured and orthotopically transplanted 12 to
14 weeks after initial implantation [98]. Although the authors demonstrated mechanical
stability without degradation, all rabbits expired due to obstruction/stenosis between 1
and 39 days after surgery.
Self-assembly techniques result in spontaneous tissue formation in the absence of
external forces: cells seeded on a non-adherent surface develop neotissue by adhering to
each other. Self-assembly in TETG has been reported using human MSC-derived cartilagi-
nous rings and cylinders generated through a custom ring-to-tube assembly system [19].
Scaffold-free TETG demonstrated similar biomechanical properties when compared to
native rat trachea.
Decellularized Constructs
Chondrocyte and epithelial cell proliferation are both needed for graft survival and
patency [98]. Cell expansion can be obtained from cells seeding onto a scaffold and
expanded in a bioreactor expansion prior transplant), in vivo (cells are seeded at the time of
implantation with the host serving as a bioreactor), or in situ (scaffold is implanted without
donor stem cells, and endogenous host cells are recruited for neotissue formation) [80].
Different MSCs have been used, ranging from bone marrow, amniotic fluid, and
adipose tissue [54].
Bone marrow-derived and adipose-derived MSC have been most used, given their
availability and accessibility [83].
The international patent application n. PCT/CN2014/078737 describes a method
for preparing decellularized animal tissues. U.S. Patent Application No. US20150079143
describes three-dimensional scaffolds obtained by lyophilization and/or electrospinning
for cell growth. International patent application no. WO2015048322 describes a method
for covering bone surface with bio-mimetic polysaccharides and facilitate transplantation.
Literature reports some examples of scaffolds made starting from decellularized matrix,
used as such as [99], or dispersing the decellularized ECM inside a synthetic polymer.
Efraim et al. [100], for example, described the development of an injectable scaffold for
cardiac tissue regeneration, based on solubilization of porcine cardiac ECM combined with
natural biomaterials (genipin and chitosan). It was possible to exploit the natural bioactivity
and the unique structure of the cardiac tissue with the processability and modelling of
the polymer.
None of these patents or works describes a complete method for covering a decel-
lularized tissue. A partial example is reported in a study by Johnson et al. [101]: in this
case, a decellularized swine trachea was reinforced with a PCL scaffold, using a 3D printer.
The advantages of this methodology include the possibility to exploit and improve the
mechanical properties of the decellularized tissue in order to avoid collapses; unfortunately,
it is difficult to scale, and it is rather elaborate. One of the most versatile methods for the
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production of porous scaffolds is the phase separation induced by diffusion (DIPS) or ther-
mally (TIPS). Scaffolds in poly-L-lactil acid (PLLA) are produced using this technique for
vascular and bronchial reconstructions. The PLLA is a biodegradable, biocompatible, and
bioabsorbable polymer whose degradation product is the lactic acid, already authorized
by the Food and Drug Administration (FDA) for in vivo application. DIPS provides three
stages: an initial coating by immersion (dip coating), one or more immersions in the coagu-
lation bath, and finally, coating by drying [102]; in the TIPS technique, the polymer solution
is cooled to the demixing temperature, cooled again at low temperature to solidify it, and
finally, washed and dried. The internal dip coating can have different shapes and sizes
(glass sheets for membranes [103], cylindrical supports for tubular scaffolding [104,105]).
By appropriately modulating some experimental parameters, it is possible to change the
characteristics of the surface, completely closed or with controlled micro-porosity. In the
first case, the construct has functions of mechanical support or protection from external
environment, in order to guarantee aseptic conditions; in the second case, the pores favor
cell growth and differentiation, and it is suitable for the internal surfaces of the scaffold.
The obtained membranes could theoretically be affixed to a decellularized tissue, but, in
practice, they need to ensure adhesion to the biological substrate and/or glue adhesion with
biocompatible glues. The scaffold can be foamed with PLLA on a decellularized matrix,
thus forming a natural/synthetic bio-hybrid tissue, so as to exploit both the mechanical
properties of PLLA and the bioactivity of the decellularized tissue during the repopulation
of the scaffold, maintaining the lumen patent for all the time necessary for regeneration.
A crucial and innovative aspect in the design and use of such synthetic materials is the
modulation of the degradation time and of regenerative response, characterized by fi-
broblastic colonization, and variation of the characteristics of the biomaterial (molecular
weight, porosity). The possibility of programming the resorption according to surgical
needs offers significant functional advantages, with important consequences in clinical
practice. In synergy with tissue growth induced by the scaffold, the use of autologous
stem cells may represent an additional stimulus to the tissue regeneration process. The
applicability of this model on medium-sized animals will open the door to a future human
study. Of particular interest will be the study of the mechanical properties of the material,
with particular reference to the possibility of being sutured, the compliance with airway
pressure variations and anastomotic seal. The consequences in terms of human health are
represented by a potential large-scale use of the prosthesis.
Few studies have shown regeneration of the tracheal cartilage. In fact, cartilage tissue
is a low cellular tissue, and subsequently, there are few cellular elements that can be
recruited. The vascularization of implanted construct is a limiting factor for the success
of the implant. Therefore, in addition to the possibility of inserting chemotactic factors
in the constructs to recruit progenitor cellular elements of the host, another viable path is
inserting multipotent cellular elements such as induced pluripotent stem cells (IPS), capable
of transforming in contact with the environment in which they are placed in tissue tracheal
cartilage and, thus, favor cellular support and repopulation. IPS can be obtained from
adult mesenchymal stem cell and, therefore, an available autologous source of cells [87].
Adult chondrocytes rapidly lose their phenotype in culture. Therefore, by isolating
cellular elements with greater potential such as IPS [106], it offers the possibility of in-
creasing cartilage formation. Thus, three-dimensional constructs have been created that
combine the biomechanical properties of polymers with the regenerative capabilities of
stem cells [107].
In Table 2, the most important attempts of tracheal reconstruction from 1994 to now
are reported.
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Table 2. Principal tracheal reconstruction attempts from 1994 to current.
Authors Methods Results
Vacanti et al. [91], 1994 Tubular scaffold from sheets of fibrouspolyglycolic acid cellularized with chondrocytes.
Implanted in four rats, as substitutes for 4–6 tracheal
rings. The animals died soon after surgery.
Kanzaki et al. [92], 2006 Prevascularized Dacron support covered by alayer of rabbit tracheal epithelial cells.
Four weeks after transplantation, the tracheal grafts
were covered by a mature, pseudostratified
columnar epithelium.
Macchiarini et al. [62], 2008
A tissue engineered tracheal graft (TETG) was
implanted in a patient with severe bronchial
stenosis following treatment for tuberculosis.
Most patients died after the implantation of
tissue-engineered airways.
Weidenbecher et al. [18], 2009
Sheets of cartilage obtained from the auricular
cartilage of New Zealand white rabbits used in
combination to a muscle/silicone.
Demonstrated mechanical stability without
degradation but all rabbits expired due to
obstruction/stenosis between 1 and 39 days
after surgery.
Naito et al. [94], 2011
Fibroblast and collagen hydrogels, mechanically
supported by osteogenically induced
mesenchymal stem cells (MSC) in ring-shaped
3D-hydrogel cultures.
Six of the nine animals died during implantation,
while three of them survived for 24 h and died the
day after.
Jungebluth et al. [68], 2011
Polymer in POSS-PCU [polyhedral
oligomericsilsesqui-oxane (POSS) covalently
linked to poly (-carbonate-urea) urethane (PCU)],
cellularized with stem cells by dynamic culture
in a bioreactor carried out urgently on a
37-year-old man.
Partial epithelial colonization of the polymer.
Hinderer et al. [14], 2012
Composite PCL–gelatin–decorine scaffold with a
three-dimensional structure and pores of an
average size of 14.4 ± 6.4 µm.
Uniform composition of the scaffold, but a poor
mechanical resistance and the presence of cells only
at the outer surface of the construct.
Gustafsson et al. [89], 2012
Rat mesenchymal stromal cells cultured on a
polyethylene terephthalate [PET] and
polyurethane [PU] scaffold and coated with
adhesion proteins.
Similar cell densities and MSC proliferating cells; no
advantages with adhesion proteins.






Huang et al. [16], 2016
PCL-based scaffold coated with an artificial
pleura patch on a 47-year-old woman affected by
tracheomalacia after tubercular disease.
Progressive improvement of the tracheal respiratory
space (from 0.3 to 1 cm in maximum diameter).
Johnson et al. [101], 2016
In vitro characterization of design and
compressive property of
3D-biofabricated/decellularized hybrid grafts
for tracheal tissue engineering.
Decellularized swine trachea was reinforced with a
PCL scaffold, using a 3D printer.
Tan et al. [83], 2017
Stent of Nitinol coated with porcine dermis,
continuously irrigated with a solution of
Ringer’s lactate with added neoangiogenic
factors and antibiotics.
Patient survived and was discharged on month after
implantation.
Ikeda et al. [106], 2017 Implantation of induced pluripotent stemcell-derived tracheal epithelial cells. Survival of tracheal epithelial tissues in rat.
Hsieh et al. [108], 2018
3D printing of tubular scaffolds with elasticity
and complex structure from multiple waterborne
polyurethanes for tracheal tissue engineering
Stability and cartilage growth.
Chan DS [109], 2019
3D-printed polycaprolactone implants to
reconstruct circumferential tracheal defects
in rabbits.
Feasibility but overgrowth of granulation tissue.
Kim et al. [107], 2020
Transplantation of a 3D-printed tracheal graft
combined with iPS cell-derived MSCs
and chondrocytes.
Evidence in forming neocartilage.
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3. Conclusions
Many advances have been made in the field of airway reconstruction research. The
ever more in-depth knowledge of the mechanisms underlying tissue regeneration with
the support of bioabsorbable scaffolds seems the way that hopefully will soon give strong
clinical results and, thus, make available to the thoracic surgeon useful tools to allow wider
resections with less disabling outcomes for patients.
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